TLR7 and neoplasm: In addition, the delivery of TLR7/8 agonist (R848)-loaded β-cyclodextrin NPs to TAMs in vivo has been demonstrated in multiple tumor models to promote M2-to-M1 repolarization, leading to the inhibition of tumor growth.